The PILGRIM Study: In Silico Modeling of a Predictive Low Glucose Management System and Feasibility in Youth with Type 1 Diabetes During Exercise
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Predictive low glucose management (PLGM) may help prevent hypoglycemia by stopping insulin pump delivery based on predicted sensor glucose values. MATERIALS AND METHODS: Hypoglycemic challenges were simulated using the Food and Drug Administration-accepted glucose simulator with 100 virtual patients. PLGM was then tested with a system composed of a Paradigm(®) insulin pump (Medtronic, Northridge, CA), an Enlite™ glucose sensor (Medtronic), and a BlackBerry(®) (Waterloo, ON, Canada)-based controller. Subjects (n=22) on continuous subcutaneous insulin infusion (five females, 17 males; median [range] age, 15 [range, 14-20] years; median [range] diabetes duration, 7 [2-14] years; median [range] glycated hemoglobin, 8.0% [6.7-10.4%]) exercised until the PLGM system suspended insulin delivery or until the reference blood glucose value (HemoCue(®); HemoCue GmbH, Großostheim, Germany) reached the predictive suspension threshold setting. RESULTS: PLGM reduced hypoglycemia (<70 mg/dL) in silico by 26.7% compared with no insulin suspension, as opposed to a 5.3% reduction in hypoglycemia with use of low glucose suspend (LGS). The median duration of hypoglycemia (time spent <70 mg/dL) with PLGM was significantly less than with LGS (58 min vs. 101 min, respectively; P<0.001). In the clinical trial the hypoglycemic threshold during exercise was reached in 73% of the patients, and hypoglycemia was prevented in 80% of the successful experiments. The mean (±SD) sensor glucose at predictive suspension was 92±7 mg/dL, resulting in a postsuspension nadir (by HemoCue) of 77±22 mg/dL. The suspension lasted for 90±35 (range, 30-120) min, resulting in a sensor glucose level at insulin resumption of 97±19 mg/dL. CONCLUSIONS: In silico modeling and early feasibility data demonstrate that PLGM may further reduce the severity of hypoglycemia beyond that already established for algorithms that use a threshold-based suspension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 1×
“2,3 Hypoglycemia diminishes counterregulatory responses (‘‘hypoglycemia begets hypo-glycemia’’ 4 ), can lead to hyperglycemia, and can contribute to glucose variability because of the release of counter-regulatory hormones and overtreatment with glucose.”
In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes
Kovatchev, B. P., Breton, M., Dalla Man, C., & Cobelli, C. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300106 · Cited by 760
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Self-citationLy, T. T., Nicholas, J. A., Retterath, A., Lim, E. M., Davis, E. A., & Jones, T. W. (2013) · JAMA · doi:10.1001/jama.2013.277818 · Cited by 411 · cited 1×
“20 In several recent studies the LGS approach has been shown to be successful in pediatric patients 21 and in patients with hypoglycemia unawareness 22 and in the large ASPIRE in-home trial 23 under outpatient conditions.”
The effect of continuous glucose monitoring in well-controlled type 1 diabetes
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0108 · Cited by 399
Fully Integrated Artificial Pancreas in Type 1 Diabetes
Breton, M., Farret, A., Bruttomesso, D., Anderson, S., Magni, L., Patek, S., Dalla Man, C., Place, J., Demartini, S., Del Favero, S., et al. (2012) · Diabetes · doi:10.2337/db11-1445 · Cited by 315
Danne, T., Mortensen, H. B., Hougaard, P., Lynggaard, H., Aanstoot, H.-J., Chiarelli, F., Daneman, D., Dorchy, H., Garandeau, P., Greene, S. A., et al. (2001) · Diabetes Care · doi:10.2337/diacare.24.8.1342 · Cited by 299
Self-citationInsulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
Buckingham, B., Chase, H. P., Dassau, E., Cobry, E., Clinton, P., Gage, V., Caswell, K., Wilkinson, J., Cameron, F., Lee, H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2303 · Cited by 169
Garg, S., Brazg, R. L., Bailey, T. S., Buckingham, B. A., Slover, R. H., Klonoff, D. C., Shin, J., Welsh, J. B., & Kaufman, F. R. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0292 · Cited by 138 · cited 4×
“20 Because of the fixed length of the 120-min suspension during LGS-On compared with LGS-Off sessions in the ASPIRE in-clinic study, the mean end-observation reference glucose was considerably higher (91.4 – 41.84 vs. 66.2 – 13.48 mg/dL) than with PLGM.”
InfluentialSelf-citationSherr, J. L., Cengiz, E., Palerm, C. C., Clark, B., Kurtz, N., Roy, A., Carria, L., Cantwell, M., Tamborlane, W. V., & Weinzimer, S. A. (2013) · Diabetes Care · doi:10.2337/dc13-0010 · Cited by 125
Self-citationAmin, R., Ross, K., Acerini, C. L., Edge, J. A., Warner, J., & Dunger, D. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.662 · Cited by 106
Cited by
Exercise management in type 1 diabetes: a consensus statement
Riddell, M. C., Gallen, I. W., Smart, C. E., Taplin, C. E., Adolfsson, P., Lumb, A. N., Kowalski, A., Rabasa-Lhoret, R., McCrimmon, R. J., Hume, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30014-1 · Cited by 903
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
“glycemia prevention with PLGS could involve a tradeoff of increased mean glucose and greater hyperglycemia in exchange for the protection of decreased hypoglycemia exposure (15,18).”
BackgroundAdolfsson, P., Riddell, M. C., Taplin, C. E., Davis, E. A., Fournier, P. A., Annan, F., Scaramuzza, A. E., Hasnani, D., & Hofer, S. E. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12755 · Cited by 191
“With current insulin pump technology, LGS function was first added followed by PLGM with the goal of basal insulin suspension at predicted hypoglycemia.(91) The level at which PLGM is activated can be individually set allowing adjustment of threshold levels, for example, during competitions and subsequent nights to pr…”
BackgroundChoudhary, P., Olsen, B. S., Conget, I., Welsh, J. B., Vorrink, L., & Shin, J. J. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0324 · Cited by 118
Lucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1065-6 · Cited by 38
Metadata
- Authors
- Danne, T., Tsioli, C., Kordonouri, O., Blaesig, S., Remus, K., Roy, A., Keenan, B., Lee, S. W., & Kaufman, F. R.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2014-06
- Volume
- 16
- Issue
- 6
- Pages
- 338-347
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W1510628726
- Cited by
- 91
- References
- 12
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.